(Medical Xpress)—Researchers from UCLA's Jonsson Comprehensive Cancer Center have discovered that specific types of bacteria that live in the gut are major contributors to lymphoma, a cancer of the white blood cells.
Jul 16, 2013
1
0
The powerful master regulatory transcription factor called Bcl6 is key to the survival of a majority of aggressive lymphomas, which arise from the B-cells of the immune system. The protein has long been considered too complex ...
Mar 3, 2013
0
0
In the first broad genetic landscape mapped of a Burkitt lymphoma tumor, scientists at Duke Medicine and their collaborators identified 70 mutations, including several that had not previously been associated with cancer and ...
Nov 12, 2012
0
0
Germinal centers are sites in the organs of the lymphatic system, formed during the course of an immune response to infection, where B cells intensely proliferate and modify their DNA in order to produce antibodies specific ...
Sep 23, 2012
0
0
A new research paper was published in Oncotarget entitled, "Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface."
Apr 16, 2024
0
0
Patients with some types of lymphoma that become resistant to standard treatments may benefit from a therapy that University of Wisconsin–Madison researchers are evaluating after they discovered a key process that fuels ...
Mar 16, 2024
0
48
A two-year follow-up clinical trial found that a new personalized cellular therapy treatment for relapsed or refractory B-cell lymphoma demonstrated strong safety and improved overall survival in patients, according to findings ...
Feb 27, 2024
0
0
A study led by the group of Didier Trono at EPFL has revealed a crucial survival tactic employed by cancer cells. The scientists have identified a group of proteins, known as "KRAB zinc finger proteins" (KZFPs), that help ...
Feb 12, 2024
0
0
As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies. In work published ...
Feb 5, 2024
0
0
Lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor (CAR) T-cell therapy, is cost-effective for second-line diffuse large B-cell lymphoma (DLBCL) therapy, according to a study published online Dec. 28 in Blood ...
Jan 4, 2024
0
0
